Manhattan Genomics, a New York-based startup, is reigniting the debate on gene-edited babies with its mission to end genetic diseases by fixing harmful mutations at the embryo stage. Co-founded by Cathy Tie, a former Thiel fellow, the company aims to make human embryo editing more acceptable in society. While the prospect of editing human embryos could potentially eliminate disease-causing mutations from future generations, it also raises ethical concerns about unintended ‘off-target’ effects and the fear of eugenics. Manhattan Genomics emphasizes that its focus is on disease correction rather than genetic enhancement, operating with transparency unlike the initial secrecy of its namesake, the Manhattan Project.<\/p>\n","protected":false},"excerpt":{"rendered":"
Manhattan Genomics, a New York-based startup, is reigniting the debate on gene-edited babies with its mission to end genetic diseases by fixing harmful mutations at the embryo stage. Co-founded by…<\/p>\n","protected":false},"author":1,"featured_media":951,"comment_status":"","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[1434],"tags":[2631,15006,6387,413,15005],"class_list":["post-12060","post","type-post","status-publish","format-standard","has-post-thumbnail","category-global","tag-biotechnology","tag-cathy-tie","tag-gene-editing","tag-global-startup-news","tag-manhattan-genomics"],"acf":[],"yoast_head":"\n